Advertisement

Comparison of Additional Regulatory Requirements for Conducting Clinical Trials on Genetically-Modified Microorganisms and Recombinant DNA in Europe, the United States, and Canada

  • King C. LeeEmail author
Article

Abstract

The number of clinical trials related to genetically-modified organisms and recombinant DNA will increase exponentially in the next decade. This article describes and compares the European, United States, and Canadian regulatory requirements for conducting clinical trials related to genetically-modified organisms and recombinant DNA. In Europe, the additional regulatory requirements include submissions and approvals from the local and national genetically-modified organisms safety committees, and the gene therapy committee (if applicable). If the genetically-modified organism is imported from another country, an “importer” certification is also required. In the United States, the additional regulatory requirements include review/approval by the institutional biosafety committee and the Recombinant DNA Advisory Committee. For gene therapy, additional information is required by the Food and Drug Administration. In Canada, review by the institutional biosafety committee (for biological hazards) and Canadian Institutes of Health Research (for research it funds) is required.

Key Words

Genetically-modified organisms DNA Clinical trials Europe United States Canada 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Guidelines for Research Involving Recombinant DNA Molecules. Bethesda, MD: National Institutes of Health; April 1988.Google Scholar
  2. 2.
    “Availability for Public Disclosure and Submission to FDA of Certain Data and Information Related to Human Gene Therapy of Xenotransplantation.” Proposed rule. Federal Register. January 18, 2001, Vol. 66, No 12.Google Scholar
  3. 3.
    United States Food and Drug Administration. “Dear Gene Therapy IND or Master File Sponsor” letter. Rockville, MD: United States Food and Drug Administration; March 6, 2000.Google Scholar
  4. 4.
    Clairmont C, Lee K, Ittensohn M, Pike J, Bermudes D, Margitich D, Kuhlman S, Li Z, Lu X, Mao J, King I, Zheng LM. Pre-clinical toxicology by VNP20009, a genetically modified Salmonella typh-imurium for treatment of solid tumors. American Association for Cancer Research, March 1998.Google Scholar
  5. 5.
    Clairmont C, Bermudes D, Low KB, Pawelek J, Pike J, Ittensohn M, Li Z, Luo X, Margitich D, Lee K, Zheng LM, King I. VNP20009, a genetically modified Salmonella typhimurium: anti-tumor efficacy, toxicology and bio-distribution in pre-clinical models. Presented at Molecular Targets and Cancer Therapeutics, American Association for Cancer Research/National Cancer Institute/European Organization for Research and Treatment of Cancer International Conference, Washington, DC, (501), 1999.Google Scholar
  6. 6.
    Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, Bermudes D, Brecher SM, Margitich D, Turnier J, Li Z, Luo X, King I, Zheng LM. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infectious Diseases. 2000;181:1996–2002.CrossRefGoogle Scholar
  7. 7.
    Doyle TW, Almassian B, Bahramian B, Bermudes D, Clairmont C, Ittenson M, King I, Krishna G, Lee K, et al. TAPET—Bacterial vectors for the delivery of peptides and proteins to solid tumors. American Association for Cancer Research, March 1999.Google Scholar
  8. 8.
    Lee KC, Zheng LM, Luo X, Clairmont C, Fischer J, Margitich D, Turnier J, Almassian B, Bermudes D, King I. Comparative evaluation of the acute toxic effects in monkeys, pigs and mice of a genetically engineered Salmonella strain (VNP20009) being developed as an antitumor agent. Int J Toxicology. 2000;19:19–25.CrossRefGoogle Scholar
  9. 9.
    Lee KC, Zheng LM, Luo X, Clairmont C, Fischer J, Margitich D, Almassian B, Bermudes D, King I. Comparative Evaluation of the Acute Toxic Effects in Monkeys, Pigs and Mice of a Genetically-Engineered Salmonella Strain (VNP20009) Being Developed as an Antitumor Agent. Society of Toxicology, March 2001.Google Scholar
  10. 10.
    Lee KC, Zheng LM, Margitich D, Almassian B, King I. Evaluation of the Acute and Subchronic Toxic Effects in Monkeys, Rats and Mice of Genetically Engineered, and E. coli Cytosine Deaminase Gene Incorporated, Salmonella Strain (TAPET-CD), Being Developed as an Antitumor Agent. Int J Toxicology. 2001;20.Google Scholar
  11. 11.
    Li Z, Lang W, Runyan JD, Luo X, Clairmont C, Shen S-Y, Bermudes D, Lin S, Chen P, Trailsmith MD, King I, Zheng LM. Tissue distribution and in vivo expression of cytosine deaminase by TAPET-CD, a genetically engineered strain of Salmonella typhimurium as an anti-tumor vector. American Association for Cancer Research, March 2001.Google Scholar
  12. 12.
    Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Lou X, Miller SI, Zheng LM, King I, Pawelek J, Bermudes D. Lipid A mutant Salmonella with suppressed virulence and TNF∝ induction retain tumor-targeting in vivo. Nature Biotech. 1999;17:37–41.CrossRefGoogle Scholar
  13. 13.
    Low KB, Ittensohn M, Lin S, Clairmont C, Luo X, Zheng LM, King I, Pawelek JM, Bermudes D. VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors. Proceedings of the American Association of Cancer Research. 1999;40:87 (Abstract 581).Google Scholar
  14. 14.
    Mier J, Olencki T, Atkins M, Sznol M, MacDonald S, Mao J, Almassian B, Lee K, Akella U, Weiss P, Bukowski R. Phase 1 trial of a live, attenuated Salmonella typhimurium (VNP20009) administered by direct intra-tumoral (IT) injection. Proceedings of the American Society of Clinical Oncology. 2001; 20:261a (abstract).Google Scholar
  15. 15.
    Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Tes. 1997;57:4537–4544.Google Scholar

Copyright information

© Drug Information Association, Inc 2002

Authors and Affiliations

  1. 1.Vion Pharmaceuticals, Inc.New HavenUSA

Personalised recommendations